{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:50:12Z","timestamp":1791348612247,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcopenia and polypharmacy are common geriatric syndromes associated with adverse outcomes in older adults. Although previous studies have suggested a potential relationship between these conditions, the independent nature of this association remains unclear, particularly among hospitalized populations. Certain medication classes may also exert muscle-protective effects that could influence this relationship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine whether polypharmacy is independently associated with sarcopenia in hospitalized older adults and to evaluate the relationship between specific medication classes and sarcopenia prevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included hospitalized patients aged\u2009\u2265\u200965 years. Sarcopenia was diagnosed according to EWGSOP2 criteria, skeletal muscle mass was assessed using bioelectrical impedance analysis (BIA), and polypharmacy was defined as the regular use of five or more medications. Medication classes with possible muscle-protective effects were identified through a targeted literature review. Multivariate logistic regression analysis was performed to assess independent associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 206 patients were included (60% female; median age: 78 years). The prevalence of sarcopenia was 39.8%. Polypharmacy was common in both sarcopenic (87.8%) and non-sarcopenic (80.6%) patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.33), and the number of medications did not differ significantly between groups (7\u2009\u00b1\u20093 vs. 7.87\u2009\u00b1\u20093;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15). Angiotensin receptor blocker (ARB) use was more frequent in the non-sarcopenic group (40% vs. 15%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). In multivariate analysis, ARB use remained independently associated with lower odds of sarcopenia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Polypharmacy was not independently associated with sarcopenia in hospitalized older adults. However, ARB use was significantly associated with lower likelihood of sarcopenia, suggesting a potential muscle-protective effect. Further longitudinal research is warranted to clarify causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40520-026-03452-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:49:27Z","timestamp":1783478967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relationship between polypharmacy, sarcopenia and drug classes in hospitalized older patients"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-4927","authenticated-orcid":false,"given":"Gorkem","family":"Turhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busra","family":"Gokce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Atmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Varli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"4","key":"3452_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","volume":"12","author":"RA Fielding","year":"2011","unstructured":"Fielding RA et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12(4):249\u2013256","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"3452_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(4):601","journal-title":"Age Ageing"},{"issue":"6","key":"3452_CR3","doi-asserted-by":"publisher","first-page":"535e1","DOI":"10.1016\/j.jamda.2015.03.003","volume":"16","author":"N Jokanovic","year":"2015","unstructured":"Jokanovic N et al (2015) Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc 16(6):535e1\u201353512","journal-title":"J Am Med Dir Assoc"},{"key":"3452_CR4","unstructured":"Gomez Jimenez E et al (2021) [Frailty prevalence in hospitalized older adults. A systematic review]. Rev Esp Salud Publica, 95"},{"issue":"5","key":"3452_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/gerona\/gly110","volume":"74","author":"DL Vetrano","year":"2019","unstructured":"Vetrano DL et al (2019) Frailty and Multimorbidity: A Systematic Review and Meta-analysis. J Gerontol Biol Sci Med Sci 74(5):659\u2013666","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"4","key":"3452_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40520-019-01136-3","volume":"31","author":"L Agosta","year":"2019","unstructured":"Agosta L et al (2019) Polypharmacy and sarcopenia in hospitalized older patients: results of the GLISTEN study. Aging Clin Exp Res 31(4):557\u2013559","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"3452_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/gerona\/glx074","volume":"73","author":"M Konig","year":"2017","unstructured":"Konig M et al (2017) Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II. J Gerontol Biol Sci Med Sci 73(1):117\u2013122","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"3452_CR8","doi-asserted-by":"publisher","first-page":"104520","DOI":"10.1016\/j.archger.2021.104520","volume":"98","author":"A Pana","year":"2022","unstructured":"Pana A et al (2022) Sarcopenia and polypharmacy among older adults: A scoping review of the literature. Arch Gerontol Geriatr 98:104520","journal-title":"Arch Gerontol Geriatr"},{"issue":"2","key":"3452_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcsm.13190","volume":"14","author":"K Prokopidis","year":"2023","unstructured":"Prokopidis K et al (2023) Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 14(2):671\u2013683","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3452_CR10","doi-asserted-by":"publisher","first-page":"111869","DOI":"10.1016\/j.exger.2022.111869","volume":"165","author":"CH Lin","year":"2022","unstructured":"Lin CH et al (2022) Effects of losartan and exercise on muscle mass and exercise endurance of old mice. Exp Gerontol 165:111869","journal-title":"Exp Gerontol"},{"issue":"21","key":"3452_CR11","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1042\/CS20210719","volume":"135","author":"J Kingsley","year":"2021","unstructured":"Kingsley J et al (2021) Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia. Clin Sci (Lond) 135(21):2503\u20132520","journal-title":"Clin Sci (Lond)"},{"key":"3452_CR12","doi-asserted-by":"publisher","first-page":"111832","DOI":"10.1016\/j.exger.2022.111832","volume":"164","author":"C Sencan","year":"2022","unstructured":"Sencan C et al (2022) DPP4 inhibitors as a potential therapeutic option for sarcopenia: A 6-month follow-up study in diabetic older patients. Exp Gerontol 164:111832","journal-title":"Exp Gerontol"},{"issue":"6","key":"3452_CR13","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jcsm.12838","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X et al (2021) Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle 12(6):1368\u20131379","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"3452_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.metabol.2014.12.005","volume":"64","author":"P Lee","year":"2015","unstructured":"Lee P et al (2015) Formoterol, a highly beta2-selective agonist, induces gender-dimorphic whole body leucine metabolism in humans. Metabolism 64(4):506\u2013512","journal-title":"Metabolism"},{"issue":"1","key":"3452_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12872-022-02804-5","volume":"22","author":"R Valdiviesso","year":"2022","unstructured":"Valdiviesso R et al (2022) Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study. BMC Cardiovasc Disord 22(1):356","journal-title":"BMC Cardiovasc Disord"},{"key":"3452_CR16","doi-asserted-by":"crossref","unstructured":"Uchitomi R, Oyabu M, Kamei Y (2020) Vitamin D and Sarcopenia: Potential of Vitamin D Supplementation in Sarcopenia Prevention and Treatment. Nutrients, 12(10)","DOI":"10.3390\/nu12103189"},{"issue":"12","key":"3452_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1532-5415.1983.tb03391.x","volume":"31","author":"S Katz","year":"1983","unstructured":"Katz S (1983) Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31(12):721\u2013727","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"3452_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179\u2013186","journal-title":"Gerontologist"},{"issue":"6","key":"3452_CR19","doi-asserted-by":"publisher","first-page":"M366","DOI":"10.1093\/gerona\/56.6.M366","volume":"56","author":"LZ Rubenstein","year":"2001","unstructured":"Rubenstein LZ et al (2001) Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol Biol Sci Med Sci 56(6):M366\u2013M372","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"3","key":"3452_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. J Psychiatr Res 12(3):189\u2013198 A practical method for grading the cognitive state of patients for the clinician","journal-title":"J Psychiatr Res"},{"issue":"1","key":"3452_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16\u201331","journal-title":"Age Ageing"},{"issue":"2","key":"3452_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/jappl.2000.89.2.465","volume":"89","author":"I Janssen","year":"2000","unstructured":"Janssen I et al (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 89(2):465\u2013471","journal-title":"J Appl Physiol"},{"issue":"3","key":"3452_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s41999-020-00297-z","volume":"11","author":"G Bahat","year":"2020","unstructured":"Bahat G et al (2020) Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP\/TIME-to-START. Eur Geriatr Med 11(3):491\u2013498","journal-title":"Eur Geriatr Med"},{"issue":"6","key":"3452_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40266-021-00855-5","volume":"38","author":"G Bahat","year":"2021","unstructured":"Bahat G et al (2021) International validation of the Turkish inappropriate medication use in the elderly (TIME) criteria set: a Delphi panel study. Drugs Aging 38(6):513","journal-title":"Drugs Aging"},{"key":"3452_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.exger.2014.07.017","volume":"58","author":"CH Lin","year":"2014","unstructured":"Lin CH et al (2014) Losartan improves measures of activity, inflammation, and oxidative stress in older mice. Exp Gerontol 58:174\u2013178","journal-title":"Exp Gerontol"},{"issue":"7","key":"3452_CR26","doi-asserted-by":"publisher","first-page":"102890","DOI":"10.1016\/j.arcmed.2023.102890","volume":"54","author":"R Qaisar","year":"2023","unstructured":"Qaisar R et al (2023) Angiotensin Receptor Blockers Restore Skeletal Muscle in Patients with Chronic Obstructive Pulmonary Disease. Arch Med Res 54(7):102890","journal-title":"Arch Med Res"},{"issue":"1","key":"3452_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jcpt.13540","volume":"47","author":"H Harada","year":"2022","unstructured":"Harada H et al (2022) Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study. J Clin Pharm Ther 47(1):89\u201396","journal-title":"J Clin Pharm Ther"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-026-03452-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03452-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03452-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:56:00Z","timestamp":1791345360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-026-03452-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s40520-026-03452-x","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ankara University Faculty of Medicine Clinical Research Ethics Committee (Approval Date: 16.01.2020 Approval No: \u01301-14-20). All participants provided written informed consent.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"202"}}